Clinical Trials Browser

Phase 1 × Completed × naxitamab × Clear all

NCT02650648 2025-07-30

Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Phase 1 Completed

Neuroblastoma